Hong Kong
Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced NSCLC
Akeso, Inc. (9926.HK) (announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2...
July 21, 2026 | News
Hong Kong Makes Its Case as Asia’s Biotech Super-Connector: Capital, Regulation and Scale Converge
Hong Kong is seeking to redefine its place in the global life sciences economy. No longer content to be viewed primarily as a financial gateway int...
July 20, 2026 | News
Takeda Partners with Insilico Medicine in Up to $600M AI Drug Discovery Collaboration
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas Insilico Medicine ("Insilico" HKEX:3696),...
July 03, 2026 | News
METiS TechBio Signs US$1.62 Billion Licensing Deal for AI-Designed Cancer Therapy with Boulevard Bio
METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, announced it has entered into an exclusive global licensing agreement ...
July 02, 2026 | News
S-CELL Launches Next-Generation Synbiotic to Naturally Support GLP-1 Production for Metabolic Health
S-CELL, a premier innovator in cellular health and anti-aging biotechnology, today announced the launch of its advanced metabolic support synbiotic (Prebio...
June 29, 2026 | News
Insilico Medicine Achieves First Clinical Milestone for AI-Designed NLRP3 Inhibitor ISM8969
Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced it has ach...
June 18, 2026 | News
Akeso Enrols First Patient in Phase Ib/II Trial of Next-Generation HER3 ADC AK138D1 for Advanced Breast Cancer
Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally...
June 17, 2026 | News
LongBio Pharma Debuts on Hong Kong Exchange With HK$10.7 Billion Valuation
LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and autoimmune diseases in China, liste...
June 08, 2026 | News
Harbour BioMed Secures US FDA Clearance For Phase I Trial Of Bispecific Cancer Antibody HBM7004
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...
May 11, 2026 | News
WuXi Biologics Advances Global Sustainability Strategy With 2025 ESG Report
Contributing to the United Nations Sustainable Development Goals, driving equitable access to healthcare through technology and innovation Enhancing gov...
May 01, 2026 | News
Ascletis Completes Enrollment For Phase II Study Of Oral GLP 1R Agonist ASC30 In Type 2 Diabetes
- 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-d...
April 27, 2026 | News
Haisco Partners With AbbVie To Advance Global Pain Therapeutics Pipeline
Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a...
April 14, 2026 | News
Ascletis Pharma Inc. Advances Oral GLP 1 And Amylin Combination For Obesity Treatment
-Fixed-dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in...
April 09, 2026 | News
Alphamab Oncology Reports Phase III Success For Anbenitamab In HER2 Positive Breast Cancer
Alphamab Oncology announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed wit...
April 06, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
